Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Three-Compartment Open Model01:06

Three-Compartment Open Model

The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

American journal of hematology·2026
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026
Same author

Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma.

Blood cancer journal·2026
Same author

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Metabolic heterogeneity and niche rewiring in bone marrow plasma cells from patients with MGUS, solitary bone plasmacytoma and multiple myeloma.

Blood cancer journal·2026
Same journal

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.3K

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

Saurabh Zanwar1, Jennifer Le-Rademacher2, Eric Durot3

  • 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 24, 2024
PubMed
Summary
This summary is machine-generated.

A new staging system for Waldenström macroglobulinemia (WM) using age, albumin, and lactate dehydrogenase (LDH) effectively stratifies patients into distinct risk groups for overall survival.

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Related Experiment Videos

Last Updated: May 7, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.3K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

Area of Science:

  • Hematology
  • Oncology
  • Clinical Prognostics

Background:

  • Waldenström macroglobulinemia (WM) patient outcomes vary significantly.
  • Existing prognostic models like the International Prognostic Scoring System may not fully capture current therapeutic landscapes.
  • The frequent assessment of MYD88 mutations necessitates updated prognostic parameters.

Purpose of the Study:

  • To re-evaluate prognostic parameters for Waldenström macroglobulinemia (WM) given advancements in therapies and diagnostic assessments.
  • To develop and validate a new prognostic model for symptomatic WM patients.

Main Methods:

  • A retrospective review of 889 treatment-naïve WM patients diagnosed between 1996 and 2017.
  • Univariate analyses identified significant clinical predictors of overall survival (OS).
  • A multivariable analysis using data from 341 patients derived a prognostic model, which was validated in an independent cohort of 335 patients.

Main Results:

  • Age, elevated serum lactate dehydrogenase (LDH), and low serum albumin (<3.5 g/dL) were independently prognostic in the derivation cohort.
  • A novel scoring system, the Modified Staging System for WM (MSS-WM), was developed using these parameters.
  • The MSS-WM model stratified patients into four distinct risk groups with significantly different 5-year overall survival rates (93% low-risk to 55% high-risk in the derivation cohort; 93% to 57% in the validation cohort).

Conclusions:

  • The Modified Staging System for WM (MSS-WM) is a simple and clinically useful prognostic tool.
  • This externally validated model reliably risk-stratifies symptomatic WM patients into four prognostic groups.
  • The MSS-WM aids in predicting overall survival and guiding clinical management decisions for WM patients.